Blockchain Registration Transaction Record

Oncotelic's Nose-to-Brain Platform Takes on Alzheimer's and Biodefense

Oncotelic Therapeutics (OTCQB: OTLC) features its intranasal nose-to-brain delivery platform in BioMedWire coverage, targeting Alzheimer's and biodefense. Learn how its technology bypasses the blood-brain barrier alongside Amgen, Johnson & Johnson, and Lunai Bioworks.

This news matters because it highlights a breakthrough approach to delivering drugs to the brain, overcoming the blood-brain barrier that has hindered treatments for Alzheimer's, brain cancers, and other CNS disorders. For patients and families affected by these conditions, Oncotelic's technology could mean more effective therapies reaching the brain faster, potentially improving outcomes and quality of life. Additionally, the biodefense applications underscore its role in national security, addressing threats from chemical or biological agents that target the nervous system. The collaboration with major pharma indicates industry validation, making this a development to watch for anyone invested in the future of neurology and biodefense.